Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,778 articles
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition...
📰
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 9.82% on an annualized basis producing an average annual return of 20.55%....
📰
Looking for a Growth Stock? 3 Reasons Why Star Equity Holdings (STRR) is a Solid Choice
Star Equity Holdings (STRR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
📰
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
📰
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?
Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
OCGN stock falls after phase II data for OCU410 show lower lesion reduction than earlier results, despite 31% improvement in the eye disease study.
📰
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
What's Behind The Jump In Corcept Therapeutics Stock?
Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) are soaring Wednesday after the FDA approved a treatment for adults with platinum-resistant...
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
BTSG and the Shift to Home Care as Margins Expand in 2026
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
BTSG Growth Drivers in 2026 Across Specialty and Providers
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
📰
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.51% on an annualized basis producing an average annual return of 13.85%....
📰
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might...
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.